JPH115749A - Pharmaceutical composition for cancer treatment - Google Patents
Pharmaceutical composition for cancer treatmentInfo
- Publication number
- JPH115749A JPH115749A JP15706397A JP15706397A JPH115749A JP H115749 A JPH115749 A JP H115749A JP 15706397 A JP15706397 A JP 15706397A JP 15706397 A JP15706397 A JP 15706397A JP H115749 A JPH115749 A JP H115749A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- mouse
- human
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、抗体を有効成分と
して含有することを特徴とする癌治療医薬品組成物に関
するものである。TECHNICAL FIELD [0001] The present invention relates to a pharmaceutical composition for treating cancer characterized by containing an antibody as an active ingredient.
【０００２】[0002]
【従来の技術】細胞が癌化すると、正常細胞では見られ
ない糖鎖が癌細胞表面に検出されることが報告されてい
る。これらは、糖蛋白質ないし糖脂質として存在してい
る。Ｎ−アセチルガラクトサミンが、蛋白質のセリンま
たはスレオニン残基にＯ−グリコシド結合している糖蛋
白質は、ムチンと総称されるが、ある種のムチンは、癌
に特異的な抗原（癌抗原）であることが知られている。2. Description of the Related Art It has been reported that when cells become cancerous, sugar chains not found in normal cells are detected on the surface of cancer cells. These exist as glycoproteins or glycolipids. Glycoproteins in which N-acetylgalactosamine is O-glycosidically linked to serine or threonine residues of proteins are collectively referred to as mucins. Certain mucins are cancer-specific antigens (cancer antigens). It is known.
【０００３】Ｈｏらは、ヒト膵癌細胞株から抽出したム
チンをマウスに免疫し、膵癌組織を特異的に認識するマ
ウスモノクローナルを産生するハイブリドーマ株を樹立
した（Ｈｏら、Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ、５１
巻、３７２頁、１９９１年）。沢田らは、Ｈｏらによっ
て作製されたマウスモノクローナルのひとつであるＮｄ
２を、ヒト膵癌を移植したマウスに投与することによ
り、マウスＮｄ２モノクローナル抗体がヒト膵癌を特異
的に認識することを証明した（Ｓａｗａｄａら、Ａｎｔ
ｉｂｏｄｙ Ｉｍｍｕｎｏｃｏｎｊｕｇａｔｅ ａｎｄ
Ｒａｄｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｌ，４巻、
４９３頁、１９９１年）。[0003] Ho et al. Immunized mice with mucin extracted from a human pancreatic cancer cell line, and established a hybridoma strain producing a mouse monoclonal that specifically recognizes pancreatic cancer tissue (Ho et al., Cancer Research, 51).
372, 1991). Sawada et al. Reported that Nd, one of the mouse monoclonals made by Ho et al.
2 was administered to mice transplanted with human pancreatic cancer, thereby proving that the mouse Nd2 monoclonal antibody specifically recognizes human pancreatic cancer (Sawada et al., Ant.
ibody Immunoconjugate and
Radiopharmaceutical, Vol. 4,
493, 1991).
【０００４】これまでに、癌抗原を認識する抗体を癌治
療に応用しようとする試みは、いくつかなされている。
しかしながら、これらはヒト抗体を用いたものである
か、または抗体に抗腫瘍剤を結合させたものが多い。[0004] Some attempts have been made to apply antibodies recognizing cancer antigens to cancer therapy.
However, many of these use human antibodies or bind antibodies to antitumor agents.
【０００５】一方、培養中の腫瘍細胞が抗体により死滅
することについて報告されており、そのメカニズムとし
て、ＡＤＣＣ（抗体特異的な細胞毒性）または補体介在
性の細胞溶解が考えられている。ＡＤＣＣの場合は、抗
体の作用はＦｃレセプターを介して起こる。即ち、抗体
を腫瘍細胞とFcレセプターを有する細胞毒性細胞ととも
に培養し、腫瘍細胞の死滅を観察することにより確認す
ることができる。しかしながら、生体内に外から抗体を
投与し抗癌効果を示すかどうかについては、個々の抗体
の特性によるところが大きく、必ずしも抗癌効果を期待
できるものではない。On the other hand, it has been reported that tumor cells in culture are killed by antibodies, and ADCC (antibody-specific cytotoxicity) or complement-mediated cell lysis is considered as the mechanism. In the case of ADCC, the action of the antibody occurs via the Fc receptor. That is, it can be confirmed by culturing the antibody together with a tumor cell and a cytotoxic cell having an Fc receptor, and observing the death of the tumor cell. However, whether or not an antibody is administered to a living body from the outside to exhibit an anticancer effect largely depends on the characteristics of each antibody, and the anticancer effect cannot always be expected.
【０００６】他方、抗体を癌の治療に用いるためには、
ヒトモノクローナル抗体が望ましい。しかしながら、癌
特異的なヒトモノクローナル抗体を作製することは技術
的に困難なことである。これに対して、ヒトの癌抗原を
ヒト以外の動物例えばマウスに免疫し、癌組織を特異的
に認識するモノクローナル抗体を取得することは比較的
容易である。On the other hand, in order to use antibodies for treating cancer,
Human monoclonal antibodies are preferred. However, it is technically difficult to produce a cancer-specific human monoclonal antibody. In contrast, it is relatively easy to immunize a non-human animal such as a mouse with a human cancer antigen and obtain a monoclonal antibody that specifically recognizes a cancer tissue.
【０００７】[0007]
【発明が解決しようとする課題】例えばマウスモノクロ
ーナル抗体を癌治療に応用する場合、抗腫瘍作用を賦与
するため、抗体に抗腫瘍剤を結合させなければならな
い。さらにマウスモノクローナル抗体を、ヒトに大量に
投与したり反復投与したりすることは、免疫応答による
アナフィラキシーの危険性や、投与した抗体が異物とし
て急速に分解を受けてしまい、その本来の活性が失われ
るなどの可能性がある。For example, when a mouse monoclonal antibody is applied to cancer treatment, an antitumor agent must be bound to the antibody in order to impart an antitumor effect. In addition, large doses or repeated administration of mouse monoclonal antibodies to humans may result in the risk of anaphylaxis due to the immune response, or the administered antibodies may be rapidly degraded as foreign substances, losing their original activity. There is a possibility that it will be done.
【０００８】近年、遺伝子工学の技術を適用して、ヒト
以外の動物種由来の抗原結合領域（可変領域）と、ヒト
由来の不変領域とからなる抗体、すなわちキメラ抗体を
取得する技術が発展してきた。先に述べた膵臓癌に特異
的なムチンを認識する抗体であるマウスＮｄ２モノクロ
ーナル抗体についても、マウス−ヒトキメラ抗体（マウ
ス−ヒトキメラＮｄ２モノクローナル抗体）の作製が報
告されている（金子ら、特開平７−２０３９７４号公
報）。In recent years, a technique for obtaining an antibody comprising an antigen-binding region (variable region) derived from an animal species other than human and a constant region derived from human, that is, a chimeric antibody has been developed by applying genetic engineering technology. Was. As for the above-mentioned mouse Nd2 monoclonal antibody which is an antibody recognizing mucin specific to pancreatic cancer, production of a mouse-human chimeric antibody (mouse-human chimeric Nd2 monoclonal antibody) has been reported (Kaneko et al., Japanese Patent Application Laid-Open No. -203974).
【０００９】[0009]
【課題を解決するための手段】本発明者らは、上記に鑑
み抗体と癌組織との反応性について鋭意検討した結果、
ヒト抗体の不変領域を含む癌特異的なキメラ抗体が抗癌
作用を有することを見出し、本発明を完成させるに至っ
た。In view of the above, the present inventors have conducted intensive studies on the reactivity of antibodies with cancer tissues,
The present inventors have found that a cancer-specific chimeric antibody containing a constant region of a human antibody has an anticancer effect, and have completed the present invention.
【００１０】即ち本発明は、癌特異的ムチンを認識する
抗体の抗原結合領域、及びヒト由来抗体の不変領域から
なる抗体を有効成分として含有することを特徴とする、
癌治療医薬品組成物である。以下本発明を詳細に説明す
る。[0010] That is, the present invention is characterized in that an antibody comprising an antigen-binding region of an antibody recognizing a cancer-specific mucin and an invariable region of a human-derived antibody are contained as active ingredients.
A pharmaceutical composition for treating cancer. Hereinafter, the present invention will be described in detail.
【００１１】本発明でいう医薬品組成物とは例えば癌の
治療薬をあげることができる。癌の治療薬としては、抗
体を用いたあらゆる方法に適用することができる。例え
ば抗体をそのまま治療薬として体内に投与する方法など
を例示することができる。The pharmaceutical composition according to the present invention includes, for example, drugs for treating cancer. As a therapeutic agent for cancer, any method using an antibody can be applied. For example, a method in which an antibody is directly administered as a therapeutic agent into the body can be exemplified.
【００１２】本発明に用いられる抗体としては、癌組織
で発現されている癌特異的ムチンを認識する抗体の抗原
結合部を含むものであり、例えば膵癌に特異的なムチン
を認識するマウスＮｄ２モノクローナル抗体の抗原結合
部などをあげることができる。 癌特異的ムチンを認識
するモノクローナル抗体を産生するハイブリドーマは、
ケーラー（Ｋｏｈｌｅｒ，Ｇ．）らの方法（Ｎａｔｕｒ
ｅ ２５６，４９５−４９７（１９７５））に従い，動
物を抗原で免疫し、脾臓細胞を取り出し、これと動物の
ミエローマ細胞とを融合して得ることができる。このよ
うなハイブリドーマとしては、マウスＮｄ２モノクロー
ナル抗体を産生するハイブリドーマ（Ｈｏら、Ｃａｎｃ
ｅｒ Ｒｅｓｅａｒｃｈ，５１巻，３７２頁，１９９１
年）が例示できる。The antibody used in the present invention includes an antigen-binding portion of an antibody that recognizes a cancer-specific mucin expressed in a cancer tissue. Examples include the antigen-binding portion of an antibody. A hybridoma that produces a monoclonal antibody that recognizes a cancer-specific mucin,
The method of Kohler, G. et al. (Natur
e 256, 495-497 (1975)), an animal can be immunized with an antigen, spleen cells can be taken out and fused with animal myeloma cells. As such a hybridoma, a hybridoma producing mouse Nd2 monoclonal antibody (Ho et al., Canc.
er Research, 51, 372, 1991
Year).
【００１３】本発明に用いられる抗体は，ヒト由来の天
然型の抗体でもよいが、遺伝子工学や蛋白質化学的方法
を用いて作製された人工型の抗体がより好ましい。遺伝
子工学的方法を用いて作製された人工型の抗体の例とし
ては、抗原との結合に必要な可変領域はマウス由来で，
不変領域はヒト由来の構造を持つマウス−ヒトキメラ抗
体が例示される。さらにヒト化型抗体でもよい。ヒト化
型抗体は、ヒト以外の動物種由来の抗原結合最少領域即
ちＣＤＲ領域と、ヒト由来のその他の可変領域と不変領
域とからなる抗体である。このような抗体の作製方法
は，それ自体当分野においてよく知られた方法により行
うことが出来る。The antibody used in the present invention may be a human-derived natural antibody, but is more preferably an artificial antibody produced by genetic engineering or protein chemical methods. As an example of an artificial antibody produced using a genetic engineering method, a variable region necessary for binding to an antigen is derived from a mouse,
The constant region is exemplified by a mouse-human chimeric antibody having a human-derived structure. Furthermore, a humanized antibody may be used. A humanized antibody is an antibody comprising an antigen-binding minimal region, ie, a CDR region, derived from an animal species other than human, and other human-derived variable regions and constant regions. Such an antibody can be produced by a method well known in the art.
【００１４】本発明の抗体の調製法としては、以下のよ
うな方法を例示することが出来る。癌特異的ムチンを認
識するモノクローナル抗体を産生するハイブリドーマを
出発材料にして遺伝子を単離し、該遺伝子を、宿主細胞
中で発現させることができ、かつヒト抗体の不変領域を
コードする遺伝子断片を含む発現ベクターに組み込む。
該ベクターにより形質転換された宿主細胞を培養して、
抗体を取得する。発現ベクターにより形質転換される宿
主細胞については、大腸菌や酵母等の微生物でも動物の
細胞でも良い。このような抗体としては、特開平７−２
０３９７４号公報に記載の癌特異的ムチンを認識するモ
ノクローナル抗体である、マウス−ヒトキメラＮｄ２モ
ノクローナル抗体が例示できる。As a method for preparing the antibody of the present invention, the following methods can be exemplified. Using a hybridoma producing a monoclonal antibody recognizing a cancer-specific mucin as a starting material, a gene is isolated, the gene can be expressed in a host cell, and contains a gene fragment encoding the constant region of a human antibody. Incorporate into expression vector.
Culturing a host cell transformed with the vector,
Obtain antibodies. The host cell transformed with the expression vector may be a microorganism such as Escherichia coli or yeast or an animal cell. Such an antibody is disclosed in JP-A-7-2.
No. 03974, a mouse-human chimeric Nd2 monoclonal antibody which is a monoclonal antibody recognizing a cancer-specific mucin can be exemplified.
【００１５】本発明で用いられる、ヒト由来抗体の不変
領域を有し癌特異的ムチンを認識する抗体は、癌治療に
関する医薬品として利用されるが、特に膵癌に対する医
薬品組成物として有用である。本発明で使用する抗体を
含んだ医薬品組成物は．当業者に既知のあらゆる手段に
よって患者に投与することができる。例えば注射は血管
内，腹腔内，皮下，又は筋肉内に行うことができる。投
与量は、抗体量として約１〜１００ｍｇ／人・日が好ま
しい。The antibody used in the present invention, which has a constant region of a human-derived antibody and recognizes a cancer-specific mucin, is used as a pharmaceutical for cancer treatment, and is particularly useful as a pharmaceutical composition for pancreatic cancer. Pharmaceutical compositions containing the antibodies used in the present invention include: It can be administered to a patient by any means known to those skilled in the art. For example, injections can be intravascular, intraperitoneal, subcutaneous, or intramuscular. The dose is preferably about 1 to 100 mg / person / day as the amount of the antibody.
【００１６】[0016]
【実施例】以下に本発明をさらに詳細に説明するために
実施例を記載するが、本発明はこれら実施例に限定され
るものではない。なお実施例では、特開平７−２０３９
７４号公報に記載の方法で得た，マウス−ヒトキメラＮ
ｄ２モノクローナル抗体を用いた。また、マウスＮｄ２
モノクローナル抗体は、Ｈｏら、ＣａｎｃｅｒＲｅｓｅ
ａｒｃｈ，５１巻，３７２頁，１９９１年に記載のもの
を用いた。EXAMPLES The present invention will be described below in more detail with reference to Examples, but the present invention is not limited to these Examples. In the embodiment, Japanese Patent Application Laid-Open No. 7-2039
No. 74, a mouse-human chimera N obtained by the method described in
d2 monoclonal antibody was used. In addition, mouse Nd2
Monoclonal antibodies are available from Ho et al., CancerRese.
Arch, vol. 51, p. 372, 1991.
【００１７】実施例１ ヌードマウスにおける膵癌ＳＷ
１９９０のマウス−ヒトキメラＮｄ２モノクローナル抗
体投与による発育阻害 ヌードマウスの膵臓に、ヒト膵癌腫セルラインであるＳ
Ｗ１９９０を接種し、１４，１７，２０，２３日目の合
計４回マウス−ヒトキメラＮｄ２モノクローナル抗体５
０μｇを腹腔内に注射した。一方、マウス−ヒトキメラ
Ｎｄ２モノクローナル抗体の代わりに、リン酸緩衝液を
投与した群を対照群とした。週に２〜３回腫瘍の生育を
観察した。Example 1 Pancreatic cancer SW in nude mice
Growth Inhibition by Administration of 1990 Mouse-Human Chimeric Nd2 Monoclonal Antibody In the Pancreas of Nude Mice, Human Pancreatic Carcinoma Cell Line S
W1990 was inoculated, and a total of four mouse-human chimeric Nd2 monoclonal antibodies 5 on days 14, 17, 20, and 23
0 μg was injected intraperitoneally. On the other hand, a group to which a phosphate buffer was administered instead of the mouse-human chimeric Nd2 monoclonal antibody was used as a control group. Tumor growth was observed 2-3 times a week.
【００１８】比較例１ ヌードマウスにおける膵癌ＳＷ
１９９０のマウスＮｄ２モノクローナル抗体投与 ヌードマウスの膵臓に、ヒト膵癌腫セルラインであるＳ
Ｗ１９９０を接種し、１４，１７，２０，２３日目の合
計４回マウスＮｄ２モノクローナル抗体５０μｇを腹腔
内に注射した。実施例１と比較例１とは同時に行い結果
を比較した。Comparative Example 1 Pancreatic cancer SW in nude mice
1990 Mouse Nd2 Monoclonal Antibody Administration The human pancreatic carcinoma cell line S was added to the pancreas of nude mice.
W1990 was inoculated, and 50 μg of mouse Nd2 monoclonal antibody was injected intraperitoneally a total of four times on days 14, 17, 20, and 23. Example 1 and Comparative Example 1 were performed simultaneously and the results were compared.
【００１９】図１は、マウス−ヒトキメラＮｄ２モノク
ローナル抗体投与マウスにおける癌細胞増殖の阻止を示
したものである。図中、左のマウスは、マウスＮｄ２モ
ノクローナル抗体投与ヌードマウスを、右のマウスは、
マウス−ヒトキメラＮｄ２モノクローナル抗体投与ヌー
ドマウスを示すもので、いずれも癌細胞接種後５０日目
のものである。図中の矢印は、腫瘍接種部を示す。図１
に示したように、マウス−ヒトキメラＮｄ２モノクロー
ナル抗体を投与したマウスの腫瘍は、マウスＮｄ２モノ
クローナル抗体を投与したマウスの腫瘍に比べ、明らか
に生育が阻害されていた。FIG. 1 shows the inhibition of cancer cell growth in mice administered with a mouse-human chimeric Nd2 monoclonal antibody. In the figure, the left mouse shows a mouse Nd2 monoclonal antibody-administered nude mouse, and the right mouse shows a mouse
FIG. 4 shows nude mice to which a mouse-human chimeric Nd2 monoclonal antibody has been administered, all of which are 50 days after inoculation of cancer cells. Arrows in the figure indicate the tumor inoculation site. FIG.
As shown in Table 2, the growth of the tumor of the mouse to which the mouse-human chimeric Nd2 monoclonal antibody was administered was clearly inhibited as compared to the tumor of the mouse to which the mouse Nd2 monoclonal antibody was administered.
【００２０】図２は、ヒト膵癌細胞ＳＷ１９９０移植マ
ウスにおける抗体投与後の生存曲線を示したものであ
る。図中、縦軸は生存しているマウスの割合を示し、横
軸は癌細胞接種後の経過日数を示した。また、１点破線
はマウスＮｄ２モノクローナル抗体投与マウス群の生存
曲線、破線は対照群マウスの生存曲線、実線はマウス−
ヒトキメラＮｄ２モノクローナル抗体投与マウス群の生
存曲線を示す。リン酸緩衝液投与の対照群及びマウスＮ
ｄ２モノクローナル抗体投与群とも、腫瘍細胞接種７０
日以内で各群の実験に用いたマウスは４匹とも死亡し
た。それに対しマウス−ヒトキメラＮｄ２モノクローナ
ル抗体を投与されたマウス群は、７０日目に１匹及び８
０日目に１匹が死亡したが、実験終了時（９５日目）に
おいても２匹が生存していた。FIG. 2 shows a survival curve after antibody administration in a mouse transplanted with human pancreatic cancer cell SW1990. In the figure, the vertical axis shows the percentage of surviving mice, and the horizontal axis shows the number of days elapsed after inoculation of cancer cells. The dashed line indicates the survival curve of the mouse group administered with the mouse Nd2 monoclonal antibody, the dashed line indicates the survival curve of the control group of mice, and the solid line indicates the mouse-
3 shows a survival curve of a group of mice administered with a human chimeric Nd2 monoclonal antibody. Control group and mouse N receiving phosphate buffer
In the group administered with the d2 monoclonal antibody, the tumor cell inoculation was 70%.
Within four days, all four mice used in the experiments in each group died. On the other hand, the group of mice to which the mouse-human chimeric Nd2 monoclonal antibody was administered had one and eight mice on day 70.
One died on day 0, but two survived at the end of the experiment (day 95).
【００２１】実施例３ ヒト膵癌細胞株ＳＷ１９９０の１×１０7個の細胞をヌ
ードマウスの大腿部皮下に注入した。腫瘍径が０．５〜
１ｃｍとなった時点（注入後１４日目）で、０．５ｍｌ
のリン酸緩衝液に１００μｇのマウス−ヒトキメラＮｄ
２モノクローナル抗体を溶解したものを１４，１５日後
に腹腔内投与し、抗体投与後経日的に腫瘍径を測定し、
腫瘍増殖抑制効果を測定した。抗体投与後７，１４日目
の腫瘍のサイズは、マウス−ヒトキメラＮｄ２モノクロ
ーナル抗体投与群で２１９±４０．４ｍｍ3及び４２７
±１９．３ｍｍ3であった。上記と同様に処置したマウ
スに生理食塩水を投与したマウスを対照群とした。対照
群の腫瘍径（７，１４日後）はそれぞれ６６７±１８
２．８ｍｍ3及び１０３０±８５．６ｍｍ3であった。以
上のように、マウス−ヒトキメラＮｄ２モノクローナル
抗体投与群は、対照群に比べ腫瘍増殖抑制効果が認めら
れた。Example 3 1 × 10 7 cells of human pancreatic cancer cell line SW1990 were subcutaneously injected into the thigh of a nude mouse. Tumor diameter 0.5 ~
0.5 ml at the time of 1 cm (14 days after injection)
100 μg of mouse-human chimeric Nd in phosphate buffer
2) Dissolved monoclonal antibody was administered intraperitoneally 14 and 15 days later, and tumor diameter was measured daily after antibody administration.
The tumor growth inhibitory effect was measured. The size of the tumor on the 7th and 14th days after the antibody administration was 219 ± 40.4 mm 3 and 427 in the mouse-human chimeric Nd2 monoclonal antibody administration group.
± 19.3 mm 3 . The mice treated in the same manner as above and administered with saline were used as control groups. The tumor diameter of the control group (after 7, 14 days) was 667 ± 18
2.8 mm 3 and 1030 ± 85.6 mm 3 . As described above, the mouse-human chimeric Nd2 monoclonal antibody-administered group exhibited a tumor growth inhibitory effect as compared with the control group.
【００２２】[0022]
【発明の効果】本発明により、癌特異的ムチンを認識す
る抗体の抗原結合領域、及びヒト由来抗体の不変領域か
らなる抗体を有効成分として含む組成物を体内に投与す
ることにより、癌治療特に膵癌の治療に有用であること
が示された。Industrial Applicability According to the present invention, a composition comprising as an active ingredient an antibody comprising an antigen-binding region of an antibody recognizing a cancer-specific mucin and a constant region of a human-derived antibody is administered to a body for cancer treatment. It has been shown to be useful in the treatment of pancreatic cancer.
【図１】マウスにおける癌細胞の増殖を示す図である。FIG. 1 shows the growth of cancer cells in mice.
【図２】膵癌移植マウスの生存曲線を示す図である。FIG. 2 shows a survival curve of a mouse transplanted with pancreatic cancer.
Claims (6)
領域、及びヒト由来抗体の不変領域からなる抗体を有効
成分として含有することを特徴とする、癌治療医薬品組
成物。1. A pharmaceutical composition for treating cancer, comprising as an active ingredient an antibody comprising an antigen-binding region of an antibody recognizing a cancer-specific mucin and a constant region of a human-derived antibody.
ることを特徴とする、請求項１に記載の癌治療医薬品組
成物。2. The pharmaceutical composition for treating cancer according to claim 1, wherein the constant region of the human-derived antibody belongs to IgG1.
来の抗体であることを特徴とする、請求項１または２に
記載の癌治療医薬品組成物。3. The pharmaceutical composition for treating cancer according to claim 1, wherein the antibody that recognizes a cancer-specific mucin is a mouse-derived antibody.
ｄ２モノクローナル抗体であることを特徴とする、請求
項１〜３いずれかの項に記載の癌治療医薬品組成物。4. An antibody recognizing a cancer-specific mucin is a mouse N
The pharmaceutical composition for treating cancer according to any one of claims 1 to 3, wherein the composition is a d2 monoclonal antibody.
抗体を有効成分として含有することを特徴とする、請求
項１〜４いずれかの項に記載の癌治療医薬品組成物。5. The pharmaceutical composition for treating cancer according to claim 1, which comprises a mouse-human chimeric Nd2 monoclonal antibody as an active ingredient.
１〜５いずれかの項に記載の癌治療医薬品組成物。6. The pharmaceutical composition for cancer treatment according to claim 1, wherein the cancer is pancreatic cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15706397A JPH115749A (en) | 1997-06-13 | 1997-06-13 | Pharmaceutical composition for cancer treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15706397A JPH115749A (en) | 1997-06-13 | 1997-06-13 | Pharmaceutical composition for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH115749A true JPH115749A (en) | 1999-01-12 |
Family
ID=15641412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15706397A Pending JPH115749A (en) | 1997-06-13 | 1997-06-13 | Pharmaceutical composition for cancer treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH115749A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021075545A1 (en) | 2019-10-18 | 2021-04-22 | 大日本住友製薬株式会社 | Humanized antibody and method for using the same |
| KR20220084135A (en) | 2019-10-18 | 2022-06-21 | 니혼 메디피직스 가부시키가이샤 | RI-labeled humanized antibody |
| WO2022149578A1 (en) | 2021-01-08 | 2022-07-14 | 日本メジフィジックス株式会社 | Production method for ac-225 solution and production method for medicine using ac-225 solution |
| WO2022225006A1 (en) | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | HUMANISED ANTIBODIES LABELLED WITH RADIONUCLIDES THAT EMIT β-RAYS |
| WO2022225007A1 (en) | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | Radioactive antitumor agent |
-
1997
- 1997-06-13 JP JP15706397A patent/JPH115749A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021075545A1 (en) | 2019-10-18 | 2021-04-22 | 大日本住友製薬株式会社 | Humanized antibody and method for using the same |
| KR20220083785A (en) | 2019-10-18 | 2022-06-20 | 스미토모 파마 가부시키가이샤 | Humanized Antibodies and Methods of Using the Same |
| KR20220084135A (en) | 2019-10-18 | 2022-06-21 | 니혼 메디피직스 가부시키가이샤 | RI-labeled humanized antibody |
| US11369701B2 (en) | 2019-10-18 | 2022-06-28 | Nihon Medi-Physics Co., Ltd. | Ri-labeled humanized antibody |
| WO2022149578A1 (en) | 2021-01-08 | 2022-07-14 | 日本メジフィジックス株式会社 | Production method for ac-225 solution and production method for medicine using ac-225 solution |
| US11752223B2 (en) | 2021-01-08 | 2023-09-12 | Nihon Medi-Physics Co., Ltd. | Method for producing Ac-225 solution and method for producing medicine using Ac-225 solution |
| WO2022225006A1 (en) | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | HUMANISED ANTIBODIES LABELLED WITH RADIONUCLIDES THAT EMIT β-RAYS |
| WO2022225007A1 (en) | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | Radioactive antitumor agent |
| KR20230174238A (en) | 2021-04-21 | 2023-12-27 | 니혼 메디피직스 가부시키가이샤 | radioactive antineoplastic agent |
| KR20230174243A (en) | 2021-04-21 | 2023-12-27 | 니혼 메디피직스 가부시키가이샤 | Humanized antibodies labeled with β-ray emitting nuclides |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100269879B1 (en) | A combination of anti-erbb-2 monoclonal antibodies and method of using. | |
| US8105594B2 (en) | Methods for amyloid removal using anti-amyloid antibodies | |
| JP4318752B2 (en) | Anti-endoglin monoclonal antibody and its use in anti-angiogenic therapy | |
| CN106456766B (en) | Antibodies against immunogenic glycopeptides, compositions comprising same and uses thereof | |
| US20220098299A1 (en) | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide | |
| EP0764030B1 (en) | Composition containing autoantibodies for tumor therapy and prophylaxis | |
| JP3066983B2 (en) | Anti-CD30 antibody that prevents proteolytic cleavage and release of membrane-bound CD30 antigen | |
| JP6326137B2 (en) | Anti-HER2 antibody and conjugate thereof | |
| KR101683884B1 (en) | Anti-epcam antibody and uses thereof | |
| US20020009430A1 (en) | Method for ex vivo immunization using heterologous intact bispecific and/or trispecific antibodies | |
| CA2325600A1 (en) | Methods for amyloid removal using anti-amyloid antibodies | |
| WO1992007466A1 (en) | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents | |
| CN109414426A (en) | Use the combination immunotherapy for cancer of arginine depletion agent | |
| US20030202973A1 (en) | Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists | |
| JP2017527544A (en) | Anti-ceramide antibody | |
| JP7510518B2 (en) | Anti-c-Met antibody-drug conjugate and its application | |
| TW201739472A (en) | Antibody-drug conjugate of an anti-glypican-3 antibody and a TUBULYSIN analog, preparation and uses | |
| JPH115749A (en) | Pharmaceutical composition for cancer treatment | |
| US20020048586A1 (en) | Therapeutic compositions that alter the immune response | |
| WO2002087611A2 (en) | Agent of human origin for vaccination against gd2 positive tumours | |
| US6007807A (en) | Induction of tumour immunity by injection of hybrid cells | |
| AT500647A1 (en) | USE OF A VACCINATE | |
| RU2822497C1 (en) | ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | |
| AU650080B2 (en) | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents | |
| AU2003262458A1 (en) | Methods for amyloid removal using anti-amyloid antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070306 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070427 |
|
| A02 | Decision of refusal |
Effective date: 20070612 Free format text: JAPANESE INTERMEDIATE CODE: A02 |